>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Human Neuroligin 3/NLGN3 is immobilized at 2 μg/mL, Biotinylated Recombinant Human Neurexin 1 beta Fc Chimera binds with a typical ED50 = 150-900 ng/mL.
Mouse myeloma cell line, NS0-derived human Neuroligin 3/NLGN3 protein Ala39-Ser709 (Ser92Tyr), with a C-terminal 6-His tag
When Recombinant Human Neuroligin 3/NLGN3 (Catalog # 9069-NL) is immobilized at 2 µg/mL, Biotinylated Recombinant Human Neurexin 1 beta Fc Chimera binds with a typical ED50 of 150-900 ng/mL.
Background: Neuroligin 3/NLGN3
Neuroligin 3 (NLGN3) is one of several type I transmembrane Neuroligin proteins that play an important role in synaptic development (1, 2). Mature human Neuroligin 3 is an approximately 120 kDa molecule that consists of a 672 amino acid (aa) extracellular domain (ECD) with a catalytically inactive cholinesterase-like domain, a 21 aa transmembrane segment, and a 118 aa cytoplasmic tail (3). Alternative splicing generates additional isoforms with 20 aa or 40 aa deletions in the ECD (3-5). Within the ECD, human Neuroligin 3 shares 99% aa sequence identity with comparable regions of mouse and rat Neuroligin 3. It is expressed during development on astrocytes and Schwann cells (6) as well as on neurons where it localizes to synaptic membranes and post-synaptic densities of both glutamatergic and GABAergic synapses (7). It associates in cis with Neuroligin 1 and Neuroligin 2 and trans-synaptically with Neurexin-1 beta, -2 beta, and -3 beta that lack the splice site 4 insertion (3, 7). A soluble form of the Neuroligin 3 ECD can be released by neurons and promotes glioma cell proliferation (8). Mutations in Neuroligin 3 enhance neuronal dendritic branching, alter both excitatory and inhibitory synaptic activity (9-12), and are associated with the development of autism spectrum disorder (13, 14).
Bemben, M.A. et al. (2015) Trends Neurosci. 38:496.
Mackowiak, M. et al. (2014) Pharmacol. Rep. 66:830.
Ichtchenko, K. et al. (1996) J. Biol. Chem. 271:2676.
Philibert, R.A. et al. (2000) Gene 246:303.
Talebizadeh, Z. et al. (2006) J. Med. Genet. 43:e21.
Gilbert, M. et al. (2001) Glia 34:151.
Budreck, E.C. and P. Scheiffele (2007) Eur. J. Neurosci. 26:1738.
Venkatesh, H.S. et al. (2015) Cell 161:803.
Etherton, M. et al. (2011) Proc. Natl. Acad. Sci. USA 108:13764.
Foldy, C. et al. (2013) Neuron 78:498.
Tabuchi, K. et al. (2007) Science 318:71.
Gutierrez, R.C. et al. (2009) Neuroscience 162:208.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Have you used Recombinant Human Neuroligin 3/NLGN3 Protein, CF?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.